Related Experiment Video

Updated: May 23, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease

M Yusuf Alsagaff1, M Thaha, M Aminuddin

  • 1Department of Cardiology and Vascular Medicine, Airlangga University School of Medicine, Jalan Mayjen Prof. Dr Moestopo 6-8, Surabaya 60118, Indonesia. yusuf_505@yahoo.com

The Journal of International Medical Research
|March 21, 2012
PubMed

Insights

Asymmetric dimethylarginine (ADMA) is linked to carotid artery thickening in patients undergoing haemodialysis. This study suggests ADMA may serve as a new marker for atherosclerosis in this population.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Biomarkers

Background:

  • End-stage renal disease (ESRD) patients on haemodialysis exhibit increased cardiovascular risk.
  • Oxidative stress plays a crucial role in the development of atherosclerosis in ESRD.
  • Carotid intima-media thickness (CIMT) is a validated marker for subclinical atherosclerosis.

Purpose of the Study:

  • To investigate the association between CIMT and oxidative stress markers, specifically asymmetric dimethylarginine (ADMA) and homocysteine.
  • To determine the predictive value of ADMA and homocysteine for atherosclerosis in haemodialysis patients.

Main Methods:

  • Cross-sectional study involving 30 patients on chronic haemodialysis.
  • Measurement of plasma ADMA and homocysteine levels using immunoassay techniques.
  • Assessment of CIMT via high-resolution ultrasonography post-haemodialysis.

Main Results:

  • A significant positive correlation was observed between CIMT and ADMA levels.
  • CIMT also correlated positively with the duration of haemodialysis.
  • ADMA levels and patient age were identified as independent determinants of CIMT, while homocysteine was not.

Conclusions:

  • Plasma ADMA levels are associated with carotid artery thickening in haemodialysis patients.
  • ADMA may represent a novel biomarker for atherosclerosis in individuals undergoing haemodialysis.
  • Further research is warranted to explore the therapeutic implications of targeting ADMA in ESRD.
Abstract

More Related Videos

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...